MDGL stock forecast
Our latest prediction for Madrigal Pharmaceuticals, Inc.'s stock price was made on the Dec. 13, 2019 when the stock price was at 97.95$.
In the short term (2weeks), MDGL's stock price should underperform the market by -6.44%. During that period the price should oscillate between -11.42% and +8.78%.
In the medium term (3months), MDGL's stock price should underperform the market by -15.04%. During that period the price should oscillate between -35.36% and +21.34%.Get email alerts
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.41$ per share.
The book value per share is 31.63$
Three months stock forecastDec. 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|